Skip to main content

Is BioCryst Pharmaceuticals A Good Biotech Stock To Own?

Growing investor interest in the bio-pharmaceuticals industry, combined with various technology innovations leading to breakthrough drug trials, have allowed BCRX to generate $19.10 million in revenues in the first quarter, ended March 31.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.